The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Strategies for mitigating CRS risk in DLBCL: preliminary findings from EPCORE NHL-1
Julie Vose, MD, University of Nebraska Medical Center, Omaha, NE, discusses cytokine release syndrome (CRS) risk mitigation in patients with diffuse large B-cell lymphoma (DLBCL). Dr Vose highlights data from a cohort of patients enrolled in the EPCORE NHL-1 trial (NCT03625037) of epcoritamab. Dexamethasone premedication and additional fluid intake prior to treatment were some strategies utilized to mitigate CRS risk, and led to a decrease in rate and severity of events, with no grade 3 CRS reported and only 3 patients (8%) experiencing grade 2. These results will aid in developing recommendations which will allow clinicians to optimize the mitigation of this treatment-related adverse event. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: Abbvie, AstraZeneca, Genmab, MEI Pharma, Genentech, Seattle Genetics, Lilly
